Global - Economy and Market
Fed won't further stimulate U.S. economy for the time being
The Federal Reserve said it doesn't plan to further stimulate the U.S. economy, whose growth is strengthening as the year ends. The central bank described the economy as "expanding moderately" and promised to keep interest rates low.
Debt crisis pushes developed economies to the edge
LONDON - The sovereign debt crisis crippling the euro zone still threatens other developed economies, leaving Britain and Japan teetering on the edge of recession but with the United States seen several paces away from a slump, a Reuters poll found.
EU to start trade talks with Egypt, Jordan, Morocco, Tunisia
BRUSSELS - European Union governments agreed on Wednesday to start trade talks with Egypt, Jordan, Morocco and Tunisia, with the aim of lowering trade barriers and bolstering economic growth in the North African and Middle Eastern states, the EU executive said.
ECB's Weidmann opposes bond-buy boost, coy on IMF
FRANKFURT - European Central Bank policymaker Jens Weidmann reiterated his opposition to the ECB ramping up its bond purchases and said his Bundesbank would only provide fresh funds for the IMF to help fight the euro zone crisis if countries beyond Europe do so too.
China sees more protectionism due to U.S., EU problems
GENEVA - China expects trade disputes to increase next year as global markets contract due to European and U.S. economic weakness, China's trade minister Chen Deming said on Wednesday.
Italy bond costs hit new high, Germany's near zero
Italy paid 6.47 percent to sell five-paper just minutes after Berlin placed 4 billion eurosof two-year bonds at an average yield of just 0.29 percent - a sign of how strongly cautious investors favour safety over returns.
U.S. stock index futures signal early gains
* U.S. stock index futures pointed to a higher open on Wall Street on Wednesday, with futures for the S&P 500 up 0.36 percent, Dow Jones futures up 0.21 percent and Nasdaq 100 futures up 0.24 percent at 1000 GMT.
Europe debt woes prompt year-end flight from risk
Asian shares fell into bear market territory for the year and commodities and the euro nursed stinging losses on Thursday, after fears that Europe's debt crisis is still worsening prompted investors to dump riskier assets and huddle in the safety of the dollar and Treasuries.
India - Economy and Market
Nov inflation eases to 9.11% MoM, yet too high
Hopes have been just crushed. November inflation has eased to 9.11% (MoM) vs 9.73 % in October. This is much higher than estimates as most experts were expecting inflation to drop below 9%.CNBC-TV18 poll had estimated it to be 8.93%.
The data shows food inflation tumbled to 8.54% in November from more than 11% in October, while fuel inflation increased to 15.48% from 14.79% and manufacturing inflation increased marginally, to 7.7%
Tax authorities unearth $12.3 bln unaccounted money - Mukherjee
NEW DELHI - Tax authorities have unearthed 660 billion rupees of unaccounted money, the finance minister told the parliament on Wednesday, as part of the government's efforts to curb tax evasion.
Government can do little to check rupee slide: Rangarajan
The slide in rupee, which fell to a new low of 53.75 against a dollar Wednesday, is driven by external factors especially general appreciation in the value of greenback.
Credit growth picks up again after a lull
After seeing a slowdown in the previous fortnight, commercial loans have again picked up in the latest fortnight ended December 2, 2011.
Government clears Rs 8,400 crore interest subsidy fund for power distribution sector
The government on Tuesday approved Rs 8,400 crore interest subsidy scheme for power distribution projects.
Rajesh Exports to import more gold for retail thrust
India's Rajesh Exports , the world's biggest jewellery maker, expects to raise gold imports 17 percent next year to power its renewed thrust.
Manmohan Singh sees FDI in retail after March - Bloomberg
NEW DELHI - Prime Minister Manmohan Singh expects to succeed in his push to open the domestic retail market to foreign companies after regional elections conclude by the end of March, according to an interview published by Bloomberg on Wednesday.
Indian shares shed 0.8 pct; sticky inflation disappoints
Indian rupee seen hitting new low again, The rupee is expected to open around 53.80 to the dollar and move in a range of 53.60 to 54.10, traders said.
Technology News –
India Inc not to trim 2012 IT budgets; plans to spend $25 billion next year: Poll
The focus of most of the companies next year is to keep maintenance costs flat and put money on new services.
Mid-sized IT company MindTree may miss Q3 target; bullish on long term growth: KK Natarajan, CEO
"Despite a traditionally weak quarter, MindTree's revenue growth will top 2.5% to 3 % this quarter, which still tops industry rates," he said.
Nokia enters mobile wallet service
Nokia India today launched its own standalone mobile wallet service to provide a secure and convenient alternative to cash on a mass scale to cellphone customers.
Lenders, investors shun debt-laden 3i Infotech; prospect of distress sale looms
3i's market cap has collapsed by Rs 900 crore so far this year, it has struggled to pay salaries and may be forced to sell assets.
World's cheapest tablet Aakash goes on sale for Rs 2500 online
Datawind, the maker of world's cheapest tablet has put up for sale about 30,000 tablets online at a price of Rs 2500 each, with a delivery period of 7 days.
After overtaking Apple as the world's largest, Samsung smartphones set to dethrone Nokia in India
If Samsung is on a roll, Nokia too is on a comeback trail and nobody dares to write it off in the great Indian smartphone battle.
Dell to increase focus on small & medium businesses
Dell India said that there were close to eight million SMBs in the country, of which about 1.5 million were adressable by IT.
Internet base in India crosses 100 million mark: What does it mean for businesses that can ride on this?
When an industry body announced in Nov crossing of that milestone, it was seen as a representation of the buzz being felt in the Indian Internet space.
Yahoo shares fall after Goldman derides company
Yahoo shares dropped on Wednesday after Goldman Sachs advised investors to sell the struggling Internet company's stock.
Inflation- November Inflation at 9.11% vs 8.2 % (YoY ) Vs 10.0 % ( MoM)
· Fuel Group -15.48 Vs 14.79% (MoM)
· Manufacturing Products - 7.7% to 7.66% ( MoM)
· Primary articles – 8.53% Vs 11.4 ( MoM)
View- Inflation hopefully should continue to reduce on account of slowing growth and its consequent favorable impact on manufactured inflation. However, double-digit increase in MSPs, and approximately 20% depreciation in the rupee since August present an upside risk to inflation.
Economics- India’s industrial production contracted 5% YoY in October, 2011 as against a growth of 2% in September, 2011 on account of -
· Slowdown in the capex cycle mainly driven by government policy rather than monetary policy.
· Basic goods (5.9 vs 6.0), Intermediate goods (0.5 vs 11.4) , Consumer durables goods ( 4.5 Vs 14.2 ), Consumer non- durables ( 2.9 Vs 4.3 ) contracted in October, 2011
· Other indicators include decline in Excise collections (YoY) for two consecutive months & deceleration in export growth
2 of 2 File(s)
FRONT PAGE 20111214.pdf
Debt Market 9-Dec-11.pdf
• AVI BioPharma, Inc. (AVII) Slashes Jobs After Failing to Ink Flu Contract More...
• McKesson Corporation Eliminates 174 Alpharetta Jobs More...
• ImmusanT, Inc. Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease More...
• Federal Trade Commission Orders Valeant Pharmaceuticals International (VRX) to Sell 3 Drugs to Acquire Dermatology Businesses More...
• Jazz Pharmaceuticals, Inc. (JAZZ) Announces Stockholder Vote in Favor of Transaction With Azur Pharma Inc. More...
• Valeant Pharmaceuticals International (VRX) Announces the Completion of the Privatization of Afexa Life Sciences Inc. More...
• Baxter International, Inc. (BAX) Signs Definitive Agreement to Acquire Synovis Life Technologies, Inc. (SYNO) More...
• Liquidia Technologies Inc. Announces Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine More...
• Intarcia Therapeutics, Inc. and Quintiles, Inc. (QTRN) Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes More...
• BioLineRx Ltd. to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen Ltd. (CGEN) More...
• Cellceutix (CTIX) Provides Updates on IND for Cancer Drug, Initiates Collaborative Agreement With Pioneer Valley Life Sciences Institute (PVLSI) for Mitochondrial Research More...
• IntelliCell BioSciences (SVFC) Announces Powerful Collaboration with Numoda Corporation More...
• Pfizer Inc. (PFE) Names Read Chairman, OKs $10 Billion in Buybacks More...
• GenVec Inc. (GNVC) President and Chief Executive Officer Announces Retirement More...
• Advanced BioScience Laboratories, Inc. Announces Hiring of Bioprocessing Specialist to GMP Manufacturing Team More...
• Essentialis Appoints Richard C. Pasternack, MD, to its Board of Directors More...
• Amarantus BioSciences, Inc. Appoints Mark J. Benedyk, PhD as Strategic Advisor More...
• AVANIR Pharmaceuticals (AVNR) Reports Fiscal 2011 Fourth Quarter and Year End Financial Results More...
• Enzo Biochem (ENZ) Reports Fiscal First Quarter 2012 Results More...
• Peregrine Pharmaceuticals, Inc. (PPHM) Reports Second Quarter 2012 Financial Results and Recent Developments More...
• Synergy Pharmaceuticals Files Suit Against Ironwood Pharmaceuticals and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie More...
• Warner Chilcott, PLC (WCRX) Announces Decision on Appeal of DORYX Preliminary Injunction More...
• Novartis AG (NVS): Patient Died After Starting Gilenya More...
• Lannett Company, Inc. (LCI) Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules More...
• Alexza Pharmaceuticals, Inc. (ALXA) Surges After FDA Panel Backs Inhaled Antipsychotic Drug More...
• Eisai Company, Ltd. (ESALY.PK) Submits Application in Japan for New Dry Syrup Formulation of its Alzheimer's Disease Treatment Aricept More...
• Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA(TM) Oral Calcitonin More...
• Results From Gentium S.p.A.'s Treatment IND for Defibrotide Presented at theAmerican Society of Hematology Annual Meeting More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Drug Cuts Myeloma Death Risk in 5-Year Study More...
• Anacor Pharmaceuticals, Inc. Announces Positive Preliminary Results from Phase 2a Trial of AN2728 and AN2898 in Atopic Dermatitis More...
• Symphogen A/S Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at American Society of Hematology More...
• Cell Therapeutics, Inc. (CTIC) and Chroma Therapeutics Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) More...
• Top-Line Phase 2 Data Indicate Repros Therapeutics Inc. (RPRX)'s Androxal(R) Normalizes Testicular Function in Men With Type 2 Diabetes More
• ADHD Drugs Don't Raise Risk of Heart Problems, Kaiser Permanente Study More...
• Blink Patterns May be a Window into Autistic Mind, Emory University School of Medicine Study More...
• Friends and Loved Ones Yawn Together, University of Pisa Study More...
• Cancer Outpatients at Greater Risk for Blood Clots, University of Rochester Medical Center Study More...
• People With DFNA2 Hearing Loss Show Increased Touch Sensitivity, Max Delbruck Center Study More...
• McKesson Corporation Eliminates 174 Alpharetta Jobs More...
• Catabasis Pharmaceuticals, Inc. Bumps Series A to $47.6 Million More...
• ImmusanT, Inc. Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease More...
• Federal Trade Commission Orders Valeant Pharmaceuticals International (VRX) to Sell 3 Drugs to Acquire Dermatology Businesses More...
• Jazz Pharmaceuticals, Inc. (JAZZ) Announces Stockholder Vote in Favor of Transaction With Azur Pharma Inc. More...
• Valeant Pharmaceuticals International (VRX) Announces the Completion of the Privatization of Afexa Life Sciences Inc. More...
• Baxter International, Inc. (BAX) Signs Definitive Agreement to Acquire Synovis Life Technologies, Inc. (SYNO) More...
• Liquidia Technologies Inc. Announces Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine More...
• Intarcia Therapeutics, Inc. and Quintiles, Inc. (QTRN) Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes More...
• BioLineRx Ltd. to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen Ltd. (CGEN) More...
• Cellceutix (CTIX) Provides Updates on IND for Cancer Drug, Initiates Collaborative Agreement With Pioneer Valley Life Sciences Institute (PVLSI) for Mitochondrial Research More...
• IntelliCell BioSciences (SVFC) Announces Powerful Collaboration with Numoda Corporation More...
• Pfizer Inc. (PFE) Names Read Chairman, OKs $10 Billion in Buybacks More...
• GenVec Inc. (GNVC) President and Chief Executive Officer Announces Retirement More...
• Advanced BioScience Laboratories, Inc. Announces Hiring of Bioprocessing Specialist to GMP Manufacturing Team More...
• Essentialis Appoints Richard C. Pasternack, MD, to its Board of Directors More...
• Amarantus BioSciences, Inc. Appoints Mark J. Benedyk, PhD as Strategic Advisor More...
• AVANIR Pharmaceuticals (AVNR) Reports Fiscal 2011 Fourth Quarter and Year End Financial Results More...
• Enzo Biochem (ENZ) Reports Fiscal First Quarter 2012 Results More...
• Peregrine Pharmaceuticals, Inc. (PPHM) Reports Second Quarter 2012 Financial Results and Recent Developments More...
• SEC Charges GlaxoSmithKline (GSK)'s Stiefel Laboratories and Its Ex-CEO of Fraud More...
• Synergy Pharmaceuticals Files Suit Against Ironwood Pharmaceuticals and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie More...
• Warner Chilcott, PLC (WCRX) Announces Decision on Appeal of DORYX Preliminary Injunction More...
• Novartis AG (NVS): Patient Died After Starting Gilenya More...
• Lannett Company, Inc. (LCI) Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules More...
• Alexza Pharmaceuticals, Inc. (ALXA) Surges After FDA Panel Backs Inhaled Antipsychotic Drug More...
• Eisai Company, Ltd. (ESALY.PK) Submits Application in Japan for New Dry Syrup Formulation of its Alzheimer's Disease Treatment Aricept More...
• Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA(TM) Oral Calcitonin More...
• Results From Gentium S.p.A.'s Treatment IND for Defibrotide Presented at theAmerican Society of Hematology Annual Meeting More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Drug Cuts Myeloma Death Risk in 5-Year Study More...
• Anacor Pharmaceuticals, Inc. Announces Positive Preliminary Results from Phase 2a Trial of AN2728 and AN2898 in Atopic Dermatitis More...
• Symphogen A/S Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at American Society of Hematology More...
• Cell Therapeutics, Inc. (CTIC) and Chroma Therapeutics Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) More...
• Top-Line Phase 2 Data Indicate Repros Therapeutics Inc. (RPRX)'s Androxal(R) Normalizes Testicular Function in Men With Type 2 Diabetes More
• ADHD Drugs Don't Raise Risk of Heart Problems, Kaiser Permanente Study More...
• Blink Patterns May be a Window into Autistic Mind, Emory University School of Medicine Study More...
• Friends and Loved Ones Yawn Together, University of Pisa Study More...
• Cancer Outpatients at Greater Risk for Blood Clots, University of Rochester Medical Center Study More...
• People With DFNA2 Hearing Loss Show Increased Touch Sensitivity, Max Delbruck Center Study More...
Two UBS bankers tried to create an offshore vehicle through which one of India's most powerful businessmen could illegally invest in securities at home, according to evidence heard in a London tribunal.
Anil Ambani, whom bank executives described as a "mega-client", was the ultimate owner behind a Mauritius-based vehicle called Pleuri, the tribunal heard.
Pleuri was established with the specific objective of investing in Indian stocks, according to evidence presented by the UK's financial regulator in a case against the former head of UBS' London-based India desk. Indian nationals and companies are not permitted to invest in Indian securities through foreign institutional investors.
Details of the controversial structure have emerged in the case of Sachin Karpe, former head of the desk that managed Indian client portfolios at UBS's wealth management division in London. Mr Karpe is challenging a £1.25m fine from the Financial Services Authority.
Mr Karpe and the other UBS banker, who cannot be named for legal reasons, have since left the Swiss bank. They allegedly misled UBS's compliance team by maintaining that Pleuri was owned by a wealthy French couple. UBS ultimately refused to sanction the structure.
"The source of funds [...] was plainly the Ambani family," Jonathan Crow QC for the FSA told the tribunal on Tuesday.
"[Mr Ambani] asked for a transaction and Sachin Karpe enabled it," said Michael Blair QC, Mr Karpe's barrister. "There was no suggestion that the client himself was damaged. The most that can be thrown at [Mr Karpe's] door was that he probably ought to have told the client that the bank would not deal with him because the transaction was not legal in India." Mr Blair described the FSA's case as "fat and splurgy".
Mr Ambani, who is not represented at Mr Karpe's tribunal hearing, has not been accused by the FSA of any wrongdoing. After the hearing, phone calls and emails to his spokesmen were not immediately returned.
The FSA alleges that in addition to trying to establish the offshore structure for Mr Ambani, Mr Karpe made unauthorised trades on other clients' accounts. To hide losses, Mr Karpe allegedly arranged loans from other clients, falsely promising them that the loans would be guaranteed by UBS at an above-market rate.
Mr Karpe is not appearing at the tribunal and not contesting an FSA ban. He claims he did not know that the Pleuri structure would be illegal. Mr Karpe is arguing against the size of the fine, and maintains the FSA overreached its powers.
After an investigation by the FSA, UBS paid a £8m fine in 2009 for not preventing the unauthorised trades. It also paid $42m in compensation to clients. UBS is supporting the FSA's case against Mr Karpe and two other ex-employees. Indian authorities have also launched their own investigations.
Mr Ambani entered into a settlement with the Securities and Exchange Board of India in January over allegations that his group misrepresented its end-of-year financial statements and violated overseas borrowing rules, without admitting any liability. As part of the Rs500m (£6.1m) settlement, the billionaire and his Reliance Infrastructure and Reliance Natural Resources companies cannot trade stocks on Indian exchanges through December 2012.